DK2440253T3 - Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller - Google Patents

Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller Download PDF

Info

Publication number
DK2440253T3
DK2440253T3 DK10786904.2T DK10786904T DK2440253T3 DK 2440253 T3 DK2440253 T3 DK 2440253T3 DK 10786904 T DK10786904 T DK 10786904T DK 2440253 T3 DK2440253 T3 DK 2440253T3
Authority
DK
Denmark
Prior art keywords
alkylphospholipid
imagination
compounds
cancer
detection
Prior art date
Application number
DK10786904.2T
Other languages
English (en)
Inventor
Jamey P Weichert
Anatoly Pinchuk
Irawati Kandela
Marc Longino
William R Clarke
Original Assignee
Cellectar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Inc filed Critical Cellectar Inc
Application granted granted Critical
Publication of DK2440253T3 publication Critical patent/DK2440253T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10786904.2T 2009-06-12 2010-06-11 Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller DK2440253T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18660009P 2009-06-12 2009-06-12
PCT/US2010/038294 WO2010144788A2 (en) 2009-06-12 2010-06-11 Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells

Publications (1)

Publication Number Publication Date
DK2440253T3 true DK2440253T3 (da) 2020-07-20

Family

ID=43306617

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20172745.0T DK3708192T3 (da) 2009-06-12 2010-06-11 Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
DK10786904.2T DK2440253T3 (da) 2009-06-12 2010-06-11 Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20172745.0T DK3708192T3 (da) 2009-06-12 2010-06-11 Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller

Country Status (8)

Country Link
US (3) US20100316567A1 (da)
EP (3) EP4248999A3 (da)
JP (2) JP6092624B2 (da)
DK (2) DK3708192T3 (da)
ES (2) ES2799411T3 (da)
RU (1) RU2012100765A (da)
SI (2) SI2440253T1 (da)
WO (1) WO2010144788A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044961B1 (en) 2004-03-02 2013-07-17 Cellectar, Inc. Phospholipid analogues for the treatment of pancreatic, ovarian and colon cancers, melanomas, gliomas, and carcinosarcomas
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
WO2010132428A1 (en) 2009-05-11 2010-11-18 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
DK3708192T3 (da) 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
EP2475400A2 (en) * 2009-09-11 2012-07-18 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
US20110064660A1 (en) * 2009-09-11 2011-03-17 Pinchuk Anatoly Deuterated alkyl phospholipid compounds, compositions, and methods of use
WO2016073737A1 (en) 2014-11-05 2016-05-12 The Regents Of The University Of California Methods of selecting and isolating cancer stem cells
DK3229810T3 (da) 2014-11-17 2020-08-17 Cellectar Biosciences Inc Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
JP6883046B2 (ja) * 2015-11-06 2021-06-02 ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 長寿命ガドリニウムに基づく腫瘍標的化イメージングおよび治療薬
JP2017135134A (ja) 2016-01-25 2017-08-03 パナソニックＩｐマネジメント株式会社 発光装置
US11147823B2 (en) * 2016-07-13 2021-10-19 Wisconsin Alumni Research Foundation Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors
US10736949B2 (en) * 2016-07-18 2020-08-11 Wisconsin Alumni Research Foundation Radiohalogenated agents for in situ immune modulated cancer vaccination
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
EP3487543A1 (en) * 2016-07-25 2019-05-29 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
JP7438756B2 (ja) * 2016-07-25 2024-02-27 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン Ｉｎ ｓｉｔｕ免疫調節癌ワクチン接種のための標的化された放射線治療用キレート
CA3082056A1 (en) * 2017-11-10 2019-05-16 Wisconsin Alumni Research Foundation Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies
KR20200143688A (ko) * 2018-04-10 2020-12-24 셀렉타 바이오사이언시스, 인코퍼레이티드 암 치료에서 인지질 에테르 유사체의 분할 투약
CN114761389A (zh) 2019-10-10 2022-07-15 塞勒科塔生物科学公司 磷脂-flavagline缀合物和将其用于靶向癌症治疗的方法
US20240131204A1 (en) * 2019-10-10 2024-04-25 Cellectar Biosciences, Inc. Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925649A (en) * 1987-06-12 1990-05-15 The University Of Michigan Radioiodinated diacylglycerol analogues and methods of use
US5347030A (en) * 1987-10-23 1994-09-13 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues and methods of using same
US5087721A (en) * 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5274113A (en) * 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5626654A (en) * 1995-12-05 1997-05-06 Xerox Corporation Ink compositions containing liposomes
US6255519B1 (en) * 1996-12-04 2001-07-03 Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US6503478B2 (en) * 1999-01-13 2003-01-07 Lightouch Medical, Inc. Chemically specific imaging of tissue
WO2001000220A2 (en) 1999-06-24 2001-01-04 The University Of British Columbia Lipoprotein lipase (lpl) variant therapeutics
JP2003088366A (ja) 2001-09-07 2003-03-25 Res Dev Found 膵臓島細胞におけるインシュリン発現を刺激する新しいホメオボックス因子
WO2003101495A1 (en) 2002-05-29 2003-12-11 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
US7220539B1 (en) * 2002-06-12 2007-05-22 The Salk Institute For Biological Studies Protein kinase B/Akt modulators and methods for the use thereof
CA2539107A1 (en) 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
US7829742B2 (en) 2003-12-22 2010-11-09 Johns Hopkins University Boronic acid aryl analogs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US7632644B2 (en) * 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
EP2044961B1 (en) * 2004-03-02 2013-07-17 Cellectar, Inc. Phospholipid analogues for the treatment of pancreatic, ovarian and colon cancers, melanomas, gliomas, and carcinosarcomas
WO2007013894A2 (en) 2004-12-20 2007-02-01 Cellectar, Llc Phospholipid ether analogs for detecting and treating cancer
US7803764B2 (en) * 2004-03-29 2010-09-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
JP2008508909A (ja) 2004-07-08 2008-03-27 セレクター，リミティド ライアビリティ カンパニー 放射性標識付きリン脂質エーテル類似体を用いる仮想結腸内視術
US20060115426A1 (en) * 2004-08-11 2006-06-01 Weichert Jamey P Methods of detecting breast cancer, brain cancer, and pancreatic cancer
US7041859B1 (en) * 2004-09-09 2006-05-09 University Of Tennessee Research Foundation Method for halogenating or radiohalogenating a chemical compound
BRPI0715783A2 (pt) 2006-08-15 2013-07-16 Cellectar Inc fluorescÊncia pràxima do infravermelho usando corantes anÁlogos de Éter fosfolipÍdico em aplicaÇÕes endoscàpicas
US7893286B2 (en) * 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
US8022235B2 (en) 2007-06-01 2011-09-20 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
US8835506B2 (en) * 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
GB0819280D0 (en) * 2008-10-21 2008-11-26 Gen Electric Imgaing and radiotherapy methods
WO2010132428A1 (en) * 2009-05-11 2010-11-18 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
DK3708192T3 (da) 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
US20110064660A1 (en) * 2009-09-11 2011-03-17 Pinchuk Anatoly Deuterated alkyl phospholipid compounds, compositions, and methods of use
EP2475400A2 (en) * 2009-09-11 2012-07-18 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use

Also Published As

Publication number Publication date
DK3708192T3 (da) 2023-11-06
WO2010144788A2 (en) 2010-12-16
JP2012530063A (ja) 2012-11-29
EP3708192A1 (en) 2020-09-16
EP4248999A3 (en) 2023-11-15
US10004818B2 (en) 2018-06-26
SI2440253T1 (sl) 2020-09-30
ES2799411T3 (es) 2020-12-17
US20130343991A1 (en) 2013-12-26
US20160228588A1 (en) 2016-08-11
SI3708192T1 (sl) 2023-12-29
JP6092624B2 (ja) 2017-03-08
JP2016011303A (ja) 2016-01-21
EP2440253B1 (en) 2020-05-13
ES2959862T3 (es) 2024-02-28
US20100316567A1 (en) 2010-12-16
US9339564B2 (en) 2016-05-17
EP4248999A2 (en) 2023-09-27
EP2440253A2 (en) 2012-04-18
WO2010144788A3 (en) 2014-03-20
EP3708192B1 (en) 2023-08-02
RU2012100765A (ru) 2013-07-20
EP2440253A4 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
DK2440253T3 (da) Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
DK2414507T3 (da) Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK3150240T3 (da) Systemer og fremgangsmåder til fremføring af terapeutiske midler
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3252057T3 (da) Multicykliske forbindelser og fremgangsmåder til anvendelse deraf
DK2598483T3 (da) Ampk-aktiverende heterocykliske forbindelser og fremgangsmåder til anvendelse af disse
DK2298099T3 (da) Indsats til dampgennemtrængelige og vandtætte såler
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
DK3133169T3 (da) Fremgangsmåder til selektion og amplificering af polynukleotider
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK3127425T3 (da) Transgen sojabønnehændelse mon87708 og fremgangsmåder til anvendelse deraf
DK3284818T3 (da) Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
DK2410981T4 (da) Tørpulverformuleringer og fremgangsmåder til behandling af lungesygdomme
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK3351558T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
DK3494972T3 (da) Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
DK2563531T3 (da) Fremgangsmåde og indretning til fordøjelse af væv
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf